Obesity-related hypertension: Epidemiology, pathophysiology, and clinical management

American Journal of Hypertension

Volumn 23, Issue 11, 2010, Pages 1170-1178

  Kotchen, Theodore A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

adipokines; blood pressure; central obesity; hypertension; insulin resistance

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL; PERINDOPRIL; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADRENERGIC SYSTEM; BARIATRIC SURGERY; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; DIET THERAPY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEALTH PROGRAM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NATRIURESIS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

ADIPOKINES; BLOOD PRESSURE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; OBESITY; PREVALENCE;

EID: 77958088160     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.172     Document Type: Review

References (101)

1. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med 1995; 333:677-685.
2. Corrigan SA, Raczynski JM, Swencionis C, Jennings SG. Weight reduction in the prevention and treatment of hypertension: a review of representative clinica trials. Am J Health Promot 1991; 5:208-214.
3. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L; NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003; 138:24-32.
4. Koh HK. A 2020 vision for health people. N Engl J Med 2010; 362:1653-1656.
5. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008 JAMA 2010; 303:235-241.
6. Institute of Medicine. Bridging the Evidence Gap in Obesity Prevention: A Framework to Improve Decision Making. National Academy of Sciences; Washington, DC. Apri 2010.
7. Cali AM, Caprio S. Obesity in children and adolescents J Clin Endocrinol Metab 2008; 93:S31-S36.
8. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA 2008; 299:2401-2405.
9. Serdula MK, Ivery D, Coates RJ, Freedman DS, Williamson DF, Byers T. Do obese children become obese adults? A review of the literature. Prev Med 1993; 22: 167-177.
10. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352:1138-1145.
11. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008 JAMA 2010; 303:242-249.
12. Misra A, Khurana L Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008; 93:S9-30.
13. Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab 2008; 93:S1-S8.
14. Popkin BM, Doak CM. The obesity epidemic is a worldwide phenomenon. Nutr Rev 1998; 56:106-114.
15. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006; 1:11-25.
16. Monteiro CA, Moura EC, Conde WL, Popkin BM Socioeconomic status and obesity in adult populations of developing countries: a review. Bull World Health Organ 2004; 82:940-946.
17. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104:2746-2753.
18. Chiang BN, Perlman LV, Epstein FH. Overweight and hypertension. A review. Circulation 1969; 39:403-421.
19. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity JAMA 1999; 282:1523-1529.
20. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867-1872.
21. Doll S, Paccaud F, Bovet P Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countr ies. Int J Obes Relat Metab Disord 2002; 26:48-57.
22. He J, Klag MJ, Whelton PK, Chen JY, Qian MC, He GQ. Body mass and blood pressure in a lean population in southwestern China. Am J Epidemiol 1994; 139:380-389.
23. Kotchen TA, Grim CE, Kotchen JM, Krishnaswami S, Yang H, Hoffmann RG, McGinley EL Altered relationship of blood pressure to adiposity in hypertension. Am J Hypertens 2008; 21:284-289.
24. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76-79.
25. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 JAMA 2003; 290:199-206.
26. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension 2002; 40:441-447.
27. Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA 2004; 291:2107-2113.
28. Paffenbarger RS Jr, Wing AL, Hyde RT, Jung DL Physical activity and incidence of hypertension in college alumni. Am J Epidemiol 1983; 117:245-257.
29. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358:1682-1686.
30. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93:S57-S63.
31. Blair D, Habicht JP Sims EA, Sylwester D, Abraham S. Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. Am J Epidemiol 1984; 119:526-540.
32. Kanai H, Matsuzawa Y, Kotani K, Keno Y, Kobatake T, Nagai Y, Fujioka S, Tokunaga K, Tarui S. Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 1990; 16:484-490.
33. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Positano V, Postano V, Buzzigoli E, Ghione S, Turchi S, Lombardi M, Ferrannini E. Visceral fat in hypertension: influence on insulin resistance and β-cell function. Hypertension 2004; 44:127-133.
34. Canoy D, Luben R, Welch A, Bingham S, Wareham N, Day N, Khaw KT. Fat distribution, body mass index and blood pressure in 22,090 men and women in the Norfolk cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) study J Hypertens 2004; 222067-2074.
35. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/nsulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97:2601-2610.
36. Meyers MR, Gokce N. Endothelial dysfunction in obesity: etiological role in atheroscls. Curr Opin Endocrinol Diabetes Obes 2007; 14:365-369.
37. O'Shaughnessy IM, Kotchen TA. Epidemiologic, physiologic, and clinica mplications of hypertension and insulin resistance. Curr Opin Cardiol 1993; 8:757-764.
38. Kidambi S, Kotchen JM, Krishnaswami S, Grim CE, Kotchen TA. Hypertension, nsulin resistance, and aldosterone: sex-specific relationships J Clin Hypertens (Greenwich) 2009; 11:130-137.
39. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362-2374.
40. Clemenz M, Kintscher U, Unger T. The metabolic syndrome: cluster with a self-fulfilling loop? J Hypertens 2006; 24:257-258.
41. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critica appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
42. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371:1927-1935.
43. Blakemore AI, Froguel P. Is obesity our genetic legacy? J Clin Endocrinol Metab 2008; 93:S51-S56.
44. Pausova Z, Jomphe M, Houde L, Vezina H, Orlov SN, Gossard F, Gaudet D, Tremblay J, Kotchen TA, Cowley AW, Bouchard G, Hamet P. A genealogical study of essential hypertension with and without obesity in French Canadians. Obes Res 2002; 10:463-470.
45. Hamet P, Merlo E, Seda O, Broecke U, Tremblay J, Kaldunski M, Gaudet D, Bouchard G, Deslauriers B, Gagnon F, Antoniol G, Pausová Z, Labuda M, Jomphe M, Gossard F, Tremblay G, Kirova R, Tonellato P, Orlov SN, Pintos J, Platko J, Hudson TJ, Rioux JD, Kotchen TA, Cowley AW J Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension. Am J Hum Genet 2005; 76:815-832.
46. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96:3423-3429.
47. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in viscera obesity Circulation 2002; 106:2533-2536.
48. Davy KP. The global epidemic of obesity: are we becoming more sympathetic? Curr Hypertens Rep 2004; 6:241-246.
49. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther 2010; 126: 159-172.
50. Weyer C, Pratley RE, Snitker S, Sprau M, Ravussin E, Tataranni PA Ethnic differencesn insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000; 36:531-537.
51. Friedman O, Log n AG. Sympathoadrenal mechanisms in the pathogenesis of sleep apnea-rela tens Rep 2009; 11:212-216.
52. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.
53. Rocchini AP, Katch V, Kveselis D, Moorehead C, Martin M, Lampman R, Gregory M. Nsulin and renal sodium retention in obese adolescents. Hypertension 1989; 14:367-374.
54. Chen J, Gu D, Huang J, Rao DC, Jaquish CE, Hixson JE, Chen CS, Chen J, Lu F, Hu D, Rice T, Kelly TN, Hamm LL, Whelton PK, He J; GenSalt Collaborative Research Group. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet 2009; 373:829-835.
55. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998; 24:789-796.
56. Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986; 57:613-618.
57. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, Kotchen TA. Association of adrenal stero ds with hypertension and the metabolic syndrome in blacks. Hypertension 2007; 49:704-711.
58. Bochud VB, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol 2007; 27:529-537.
59. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-nduced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41-47.
60. Willenberg HS, Schinner S, Ansurudeen I. New mechanisms to contro aldosterone synthesis. Horm Metab Res 2008; 40:435-441.
61. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stroma cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 1999; 140:3188-3196.
62. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl Jr, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice J Clin Invest 2003; 112:83-90.
63. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44:12-19
64. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45:356-362.
65. Yusuf S, Sleight P Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study I nvestigators. N Engl J Med 2000; 342:145-153.
66. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45:9-14.
67. Yasue S, Masuzaki H, Okada S, Ishii T, Kozuka C, Tanaka T, Fujikura J, Ebihara K, Hosoda K, Katsurada A, Ohashi N, Urushihara M, Kobori H, Morimoto N, Kawazoe T, Naitoh M, Okada M, Sakaue H, Suzuki S, Nakao K. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status a pertrophy. Am J Hyperten 23:425-431.
68. Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol 2009; 302:111-117.
69. Pierce GL, Beske PGL, Lawson BE, Southall KL, Benay FJ, Donato AM, Seals DR. Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight/obese adults. Hypertension 2008; 52:72-79.
70. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity J Clin Endocrinol Metab 2008; 93:S64-S73.
71. Correia ML, Haynes WG. Obesity-related hypertension: is there a role for selective eptin resistance? Curr Hypertens Rep 2004; 6:230-235.
72. Galletti F, D'Elia L, Barba G, Siani A, Cappuccio FP, Farinaro E, Iacone R, Russo O, De Palma D, Ippolito R, Strazzullo P. High-circulating leptin levels are associated with greater risk of hypertension in men independently of body mass and insulin resistance: results of an eight-year follow-up study J Clin Endocrinol Metab 2008; 93:3922-3926.
73. Asferg C, Møgelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, Appleyard M, Jensen GB, Jeppesen J. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens 2010; 23:327-333.
74. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of eptin-mediated defects. J Clin Endocrinol Metab 1999; 84:3686-3695.
75. Mark AL, Agassandian K, Morgan DA, Liu X, Cassell MD, Rahmouni K. Leptin signaling in the nucleus tractus solitarii increases sympathetic nerve activity to the kidney. Hypertension 2009; 53:375-380.
76. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic n rvous system. Hypertension 2003; 41:1072-1079.
77. Villarreal D, Reams G, Freeman RH, Taraben A. Renal effects of leptin in normotensive, hypertensive, and obese rats. Am J Physiol 1998; 275: R2056-R2060.
78. Yiannikouris F, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. Curr Opin Nephrol Hypertens 2010; 19:195-200.
79. Kotchen TA. Attenuation of experimental hypertension with agents that increase nsulin sensitivity Drug Dev Res 1994; 32:100-103.
80. Katz DL, O'Connell M, Yeh MC, Nawaz H, Njike V, Anderson LM, Cory S, Dietz W; Task Force on Community Preventive Services. Public health strategies for preventing and controlling overweight and obesity in school and worksite settings: a report on recommendations of the Task Force on Community Preventive Service MMWR Recomm Rep 2005 54:1-12.
81. Summerbell CD, Edmunds WE, Kelly SAM, Brown T, Campbell KJ. Interventions for preventing obesity in children. Cochrane Database Syst Rev 2005: CD001871.
82. Romon M, Lommez A, Tafflet M, Basdevant A, Oppert JM, Bresson JL, Ducimetière P, Charles MA, Borys JM. Downward trends in the prevalence of childhood overweight in the setting of 12-year school-and community-based programmes. Public Health Nutr 2009; 12:1735-1742.
83. Westley H. Thin living. BMJ 2007; 335:1236-1237.
84. Bray GA. Lifestyle and pharmacological approaches to weight loss: efficacy and safety J Clin Endocrinol Metab 2008; 93:S81-S88.
85. Hill JO. Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 2006; 27:750-761.
86. Gl Network Obesity Study Group. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med 2010; 164:116-123.
87. Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab 2008; 93:S89-S96.
88. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension J Hypertens 2002; 20:1873-1878.
89. Sjöström CD, Peltonen M, Wedel H, Sjöström L Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36:20-25. (Pubitemid 30602147)
90. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42:878-884.
91. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight oss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005; 45:1035-1041.
92. Frohlich ED. Clinical management of the obese hypertensive patient. Cardiol Rev 2002; 10:127-138.
93. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64:2537-2565.
94. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, bsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Opari S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
95. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? Hypertens 2001; 19:667-674.
96. Zanella MT, Kohlmann O Jr, Ribeiro AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001; 38:705-708.
97. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl Med 2006; 355:1551-1562.
98. Czernichow S, Ninomiya T, Huxley R, Kengne AP, Batty GD, Grobbee DE, Woodward M, Neal B, Chalmers J. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension 2010; 55:1193-1198.
99. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML Lisinopri versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30:140-145.
100. Wenzel UO, Krebs C. Management of arteria hypertension in obese patients. Curr Hypertens Rep 2007; 9:491-497.
101. Jordan J, Engeli S, Redon J, Sharma AM, Luft FC, Narkiewicz K, Grassi G; European Society of Hypertension Working Group on Obesity European Society of Hypertension Working Group on Obesity: background, aims and perspectives. J Hypertens 2007; 25:897-900.